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Background: The Consortium for Southeastern Hypertension Control (COSEHC) promotes 
global risk factor management in patients with metabolic syndrome. The COSEHC Global Vas-
cular Risk Management Study (GVRM) intends to quantify these efforts on long-term patient 
outcomes. The objectives of this study were to present baseline demographics of patients enrolled 
in the GVRM, calculate a modified COSEHC risk score using 11 variables (COSEHC-11), and 
compare it with the original COSEHC-17 and Framingham, Prospective Cardiovascular Münster 
(PROCAM), and Systemic Coronary Risk Evaluation (SCORE) risk scores.
Methods: Deidentified electronic medical records of enrolled patients were used to calculate the 
risk scores. The ability of the COSEHC-11 score to predict the COSEHC-17 score was assessed 
by regression analysis. Raw risk scores were converted to probability estimates of fatal coronary 
heart disease (CHD) and compared with predicted risks from other algorithms.
Results: Of the 177,404 patients enrolled, 43,676 had data for all 11 variables. The 
  COSEHC-11 score (mean ± standard deviation) of these 43,676 patients was 31.75 ± 11.66, 
implying a five-year fatal CHD risk of 1.4%. The COSEHC-11 score was highly predictive of the 
COSEHC-17 score (R2 = 0.93; P , 0.0001) and correlated well with the SCORE algorithm.
Conclusion: The COSEHC-11 risk score is statistically similar to the COSEHC-17 risk score 
and should be a viable tool for evaluating its ability to predict five-year cardiovascular mortal-
ity in the coming years.
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Introduction
Metabolic syndrome refers to a constellation of cardiovascular risk factors. Although 
several different definitions of metabolic syndrome exist,1 the US National Cholesterol 
Education Program Adult Treatment Panel III defines metabolic syndrome as the pres-
ence of at least three of five core risk factors: abdominal obesity; insulin resistance, glu-
cose intolerance, or drug treatment for elevated glucose levels; elevated blood pressure 
or antihypertensive drug treatment; low levels of high-density lipoprotein cholesterol 
(HDL-C); and elevated triglyceride levels.2 Other factors commonly associated with 
the metabolic syndrome include vascular inflammation, presence of a prothrombotic 
state, physical inactivity, aging, and a genetic predisposition.3–5
Improved management of these risk factors is important because the metabolic 
syndrome strongly predicts the development of cardiovascular disease (CVD).6–8 In 
a large meta-analysis of 172,573 individuals enrolled in longitudinal studies, per-
sons with metabolic syndrome had almost a twofold increased risk of experiencing 
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(summary risk ratio [RR], 1.78; 95% confidence interval: 
1.58, 2.00).6 The risk remained significant even when adjust-
ing for known cardiovascular risk factors or a history of CVD. 
Furthermore, there appears to be a gender effect such that 
women have a greater risk than men (summary RR, 2.63 
versus 1.98; P = 0.09)6 and a continuum of risk that increases 
with the number of metabolic syndrome components   
present.9,10
While the American Heart Association and the American 
College of Cardiology11 recommend using the Framingham 
Heart Study global risk assessment scoring system12 for esti-
mating an individual’s 10-year risk of experiencing a fatal 
or nonfatal cardiovascular event, this approach has several 
limitations13 that are underscored by the more comprehen-
sive global hypertension management guidelines put forth 
by the European Society of Hypertension and European 
Society of Cardiology.14 Although the Framingham scoring 
system includes the “standard” risk factors of smoking, 
blood pressure, total cholesterol, HDL-C, blood glucose, 
sex, and age, exclusion of other recognized risk factors 
such as left ventricular hypertrophy (LVH) limits its ability 
to discriminate sensitively between individuals at different 
levels of cardiovascular risk.15 Equally important, the gen-
eralized application of the Framingham risk score to both 
sexes and all racial and ethnic groups has been questioned, 
because the Framingham study was conducted among 
5208 predominantly white, healthy individuals living in 
Framingham, Massachusetts.12,13,16 For example, in a study 
that assessed the multiethnic, multiracial applicability of the 
Framingham risk score, the score was found to be generally 
predictive for whites and blacks, but systematically overes-
timated five-year risk in Japanese American and Hispanic 
men and Native American women.12 Other studies reported 
that the Framingham score also overestimates risk in patients 
from China,17 The Netherlands,18 and Ireland and France.19 
To address these limitations, other risk scoring tools have 
been developed, including the Prospective Cardiovascular 
Münster (PROCAM) score, which estimates the 10-year 
risk of fatal and nonfatal cardiovascular events,20 and the 
Systemic Coronary Risk Evaluation (SCORE) score, or 
Weibull algorithm,21 which estimates the 10-year risk of 
fatal cardiovascular events.
In an effort to develop a more accurate and valid risk 
score for predicting CVD mortality in the southeastern US, 
a region with a highly diverse population and a historically 
higher prevalence of CVD and CVD-related mortality,22,23 
the Consortium for Southeastern Hypertension Control 
(COSEHC) developed an alternative global approach to 
screening and scoring patients for cardiovascular risk. The 
COSEHC risk tool includes 17 risk factors and is based 
on the   cardiovascular risk score published by the INdi-
vidual Data ANalysis of Antihypertensive intervention 
trials (INDANA) database study,24 which included 11 vari-
ables.25,26 The INDANA algorithm calculates the five-year 
risk of death from CVD. It was derived with data from eight 
large randomized trials (n = 48,088), all of which assessed 
antihypertensive drugs versus no intervention and reported 
mortality by intention to treat. Furthermore, the trials were 
multinational, which enhanced generalizability, and because 
follow-up in these trials was stringent, the risk estimators 
developed were precise.
To validate the discriminative value of the COSEHC 
risk tool in predicting CVD mortality in the diverse popu-
lation of the southeastern US, the Global Vascular Risk 
Management (GVRM) study was initiated. This large-scale 
prospective study was designed to determine the sensitivity 
of the COSEHC risk tool. The GVRM also seeks to deter-
mine if the COSEHC risk tool can be useful in improving 
quality of care in the management of vascular disease and 
the metabolic syndrome by providing benchmarking data on 
treatment patterns and outcomes to participating COSEHC 
Cardiovascular Centers of Excellence™ and in assessing the 
effect of COSEHC-designated treatment goals26 on patient 
outcomes at five years.
In this article, the demographic profile and risk factor 
prevalence of the GVRM study population at baseline are 
presented, the development of the COSEHC-11 risk score 
tool is described, and the COSEHC-11 score is compared 
with the original COSEHC-17 risk score tool, as well as the 
Framingham, PROCAM, and SCORE (Weibull) risk score 
algorithms.
Methods
study design
The GVRM study is a voluntary, observational, prospective 
quality improvement initiative conducted at eight COSEHC 
Cardiovascular Centers of Excellence. The   Centers of 
Excellence network, established in 1998, represents a 
cooperative initiative of expert health care providers who 
partner with local health, consumer, employer, and academic 
groups to develop programs that focus on the treatment, 
clinical research, and prevention of metabolic syndrome-
related CVD. Data were derived from patients who were 
aged $18 years and met one or more of the following cri-
teria: at least one predefined International Classification of 
Diseases, 9th Revision (ICD-9) code corresponding to CVD Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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or risk factors, treatment at a cardiac or vascular-related 
clinic or department of a participating Center of Excellence, 
or treatment at a noncardiac-related outpatient clinic associ-
ated with a cardiac-related Current Procedural Terminology 
code. Because this is an observational study, all patients 
from each participating center are treated per the standard 
of care for their respective conditions, and no predefined 
visits, medical or laboratory tests, procedures, or interven-
tions are required.
The 11 variables used in calculating the modified COSE-
HC-11 risk score are listed in Table 1. Additional variables 
of interest include those required to calculate the original 
COSEHC-17 risk score (Table 1). Of the 11 variables necessary 
to calculate the modified COSEHC score, age, sex, smoking 
status, and family history of coronary heart disease (CHD) are 
collected only once; all other data are updated on a quarterly 
basis from the individual centers and submitted to COSEHC.
study duration and outcomes
A five-year prospective study is planned from a baseline data 
date of February 4, 2010. The main outcome measures are 
cardiovascular morbidity and mortality, including the devel-
opment of CHD, congestive heart failure, stroke, transient 
ischemic attack, abdominal aortic aneurysm, myocardial 
infarction, death, renal failure, and diabetic retinopathy.
Data flow and management
The GVRM study was approved at a central level by the 
Copernicus Group Institutional Review Board (Research 
Triangle Park, NC). Individual patient electronic medical 
records from participating COSEHC Centers of Excellence 
sites are submitted to the COSEHC Coordinating Center at 
the Wake Forest University School of Medicine on a quar-
terly basis. The Coordinating Center includes a scientific 
advisory board to provide guidance on data interpretation 
and analytic review. The cutoff for inclusion of data in the 
baseline analysis was February 4, 2010. The Coordinating 
Center maintains a master electronic medical record for each 
patient, which includes all treatments, laboratory records, 
and clinical events. In order to comply with all local and 
federal privacy acts, including Health Insurance Portabil-
ity and Accountability Act requirements, all patient-level 
data are deidentified prior to analysis. The deidentification 
process involves assigning each unique patient record a 
deidentified key that consists of a three-character center ID 
and a sequential number from 1 to n and the conversion of 
all calendar dates to days since date of birth. Deidentified 
data are sent for analysis to ICON Clinical Research (North 
Wales, PA) along with the patient’s unique key, age, sex, 
and ethnic background (white, black, Hispanic, other). These 
data include converted visit dates expressed in terms of days 
Table 1 Variables included in the original COSEHC, modified COSEHC, Framingham, SCORE (Weibull), and PROCAM cardiovascular 
risk scores
Variable Modified 
COSEHC
Original 
COSEHC25   
Framingham 
Heart Study12
SCORE21 PROCAM20
Age, years
sex
Total cholesterol, mmol/L
HDL-c, mmol/L
LDL-c, mmol/L
Triglycerides, mmol/L
systolic blood pressure, mmHg
Smoking status (yes or no)
Diabetes mellitus,a mmol/L
Diabetes mellitus (yes or no)
Family history of premature cHDb 
(yes or no)
 
ECG-confirmed LVH (yes or no)
Height, inches
serum creatinine, μmol/L
Homocysteine, μmol/L
Prior MI (yes or no)
Prior stroke (yes or no)
Notes: grey shading indicates the variable is included in the calculation of the risk score. aDiabetes diagnosis based on fasting blood glucose .6.66 mmol/L listed in electronic 
medical record; bFor cOseHc score, required only for males aged ,60 years. 
Abbreviations: cHD, coronary heart disease; cOseHc, consortium for southeastern Hypertension control; ecg, electrocardiogram; HDL-c, high-density lipoprotein 
cholesterol; LDL-c, low-density lipoprotein cholesterol; LVH, left ventricular hypertrophy; Mi, myocardial infarction; PROcAM, Prospective cardiovascular Münster; 
scORe, systemic coronary Risk evaluation.Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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since birth. The data will never be “reidentified,” and ICON 
will never have access to actual calendar dates.
statistical methods
The COSEHC-11 risk score is an additive score calculated 
using separate algorithms for men and women. The individual 
scoring elements are for age (five-year ranges), smoking 
status (with differential scores for each age range), systolic 
blood pressure ranges, laboratory test score ranges, and 
patient history variables. The final COSEHC-11 score is 
the sum of each of these individual scoring elements. The 
primary baseline analysis for this article involved the calcula-
tion of the COSEHC-11 risk score and included only those 
patients with all 11 required data elements. An exception for 
this requirement was made for women and men aged .59 
years with missing data for family history of myocardial 
infarction. This exception is made because the COSEHC 
risk score only uses premature family CHD for male patients 
aged ,60 years. For the current report, the following applies: 
if a patient had multiple visits during the six months prior to 
the end of the baseline period (February 4, 2010), data from 
the last visit were used; if laboratory values or blood pressure 
readings were missing from the last visit, data from the most 
recent prior visit were used, with a maximum carry-forward 
time of 12 months; and patient history variables (ie, smok-
ing and diabetes status, family CHD history, and LVH) had 
unlimited carry-forward times.
The impact of using ,11 variables to estimate the modi-
fied COSEHC-11 risk score was gauged by including patients 
with incomplete data. Only patients with $8 of 11 variables 
were considered for this analysis. Three methods of data 
imputation were used to improve the accuracy of the modified 
COSEHC risk score. The first imputation method increased 
the amount of time that laboratory and blood pressure val-
ues were carried forward to replace missing values; thus, 
instead of the original cutoff time of 12 months, unlimited 
carry-forward was used. The second imputation augmented 
the results of the first imputation with pharmacy data. When 
patients were missing data for diabetes status, we checked 
for the presence of diabetes-specific medications (ie, insulin 
detemir, insulin glargine, human recombinant insulin, insulin 
lispro, metformin, pioglitazone, and rosiglitazone). Patients 
with at least one of these medications had their diabetes sta-
tus changed from “missing” to “diabetic.” Lastly, multiple 
imputations were implemented using SAS® PROC MI (SAS 
Institute, Inc., Cary, NC) with the Markov chain Monte Carlo 
(MCMC) method. The MCMC method can be used when 
some of the missing variables (eg, laboratory tests) have 
arbitrarily missing patterns.27 MCMC simulation constructs 
a Markov chain that is long enough for the distribution of the 
elements to stabilize to a stationary distribution (the distribu-
tion of interest). Through repeated simulations of the steps of 
this chain, the method simulates draws from the distribution 
of interest.27 This allows for simulations from a wide range 
of distributions without being computationally burdensome.28 
For the COSEHC dataset, a set of mean and covariance 
priors were created using data from site 4 (n = 1319), which 
had complete data on all patients and good laboratory test 
compliance. These priors were used by the MCMC algorithm 
to improve its imputation.
To validate the modified COSEHC score, a regression 
analysis was used to estimate the full COSEHC-17 score 
using the modified COSEHC-11 score as a predictor. To 
perform this analysis, the original COSEHC-17 risk score was 
calculated for the subgroup of patients with complete data for 
all COSEHC-17 variables. The modified COSEHC-11 risk 
score was also calculated for this subgroup. The modified 
COSEHC-11 risk score was used as the only predictor for 
the full COSEHC-17 risk score using linear regression. This 
analysis was performed to demonstrate that the COSEHC-11 
risk score could serve as a proxy for the full COSEHC-17 risk 
score. In addition, we used the results from this regression 
analysis to transform the modified COSEHC-11 risk score 
into an estimated CHD event probability and to character-
ize the distribution of CHD event risk within the study 
population.
To compare the modified COSEHC risk score and its 
resulting event probability with other risk indices, the subset 
of patients who had complete data for all 11 variables to cal-
culate Framingham, PROCAM, and SCORE (Weibull) risk 
scores was used. These risk scores were calculated using both 
the nonimputed and multiple imputation datasets. It should 
be noted that the SCORE (Weibull) risk score predicts the 
10-year risk of fatal CHD events, whereas the Framingham 
and PROCAM risk indices predict both fatal and nonfatal 
events over 10 years. Table 1 lists the required data elements 
for each risk score. All data are reported as mean ± 1 standard 
deviation (SD) of the mean.
Results
Baseline demographics
A total of 177,404 patients from eight participating COSEHC 
centers were found to be eligible for inclusion in the GVRM 
study and represent the baseline population. Of these patients, 
70,567 had at least 8 out of 11 required COSEHC variables 
present in their electronic medical record, including 43,676 Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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who had complete data for all 11 variables. Table 2 pres-
ents the characteristics of the 70,567 patients with eight 
or more data elements complete. Of these 70,567 patients, 
the mean age was 60 years and 54% were women. Dia-
betes mellitus was present in 35% of the 65,391 patients 
for whom the status was available. The most commonly 
missing data elements among this group were for ethnicity, 
family CHD history, and clinical diagnosis of LVH. Of the 
18,725 patients whose race or ethnicity was known, 70% 
were white, 20% were black, 1% were Hispanic, and 8% 
were classified as other.
cOseHc-11 scores
COSEHC-11 scores were calculated for the 43,676 patients 
with complete baseline data for all 11 variables. As can be 
seen in Table 3, data completeness varied across the centers, 
with the proportion of patients for whom complete base-
line data were available for all 11 variables ranging from 
0.3% (center 7) to 63.4% (center 3). Among the 43,676 
patients with complete data, the mean COSEHC-11 score 
was 31.75 ± 11.66. The range across the centers was 30.93 
to 36.85. One interesting finding is the relative stability of 
the SD across sites and between the individual sites and the 
total cohort (Table 3).
Table 3 also displays the COSEHC-11 scores that result 
from the three methods of data imputation. The first method 
of imputation, with no limit on carry-forward time, resulted 
in the availability of 43,861 patients for analysis, an increase 
of 185 patients over no imputation. The relatively small 
number of additional patients is consistent with the avail-
ability of complete laboratory and blood pressure records 
for most patients (Table 2). The second method of imputa-
tion (pharmacy imputation of diabetes medications), which 
could only add patients with diabetes, added no additional 
patients. While there were 5176 patients with a missing 
diabetes history, patients with no diabetes records were typi-
cally missing other patient history variables in addition to 
their diabetes status. Thus, the imputation using pharmacy 
records did not produce any new complete records, although 
it did find 79 patients from this group with a positive history 
of diabetes-specific medications.
The MCMC method of imputation increased the sample 
size from 43,676 to 70,567. The average COSEHC-11 score 
in the imputed group decreased slightly from 31.75 ± 11.66 
to 31.24 ± 11.24 (Table 3). Center 7, which had the fewest 
number of patients with available data for all 11 variables, 
showed the largest change in risk score upon imputation, 
decreasing from 36.85 ± 11.13 to 32.12 ± 10.94. Of the 
five sites having $1000 patients with complete data for 
all 11 variables, multiple imputation changed the average 
COSEHC-11 score by ,one point.
comparison of cOseHc-11  
and cOseHc-17 scores
Figure 1 shows the results of a linear regression model 
of the more comprehensive COSEHC-17 score using the 
COSEHC-11 score as the predictor. This regression was 
performed on the subset of 735 patients who had avail-
able data for all 17 COSEHC variables except homo-
cysteine. (Homocysteine levels were available for only 
one patient in this cohort and were therefore excluded as 
a required variable.) The COSEHC-11 coefficient was a 
statistically significant predictor of the COSEHC-17 score 
(P , 0.0001; R2 = 0.93). This suggests that the COSEHC-11 
risk score is highly correlated with the full COSEHC-17 
risk score, and that a simple linear transformation of the 
COSEHC-11 score can yield a good approximation of the 
full COSEHC-17 risk score, and therefore, cardiovascular 
event probability.
Table  2  Baseline  demographics  of  the  70,567  patients  with   
$eight cOseHc-11 variables
Variables Descriptive  
statistic
Na
Age, years 60 ± 14 70,567
Women, n (%) 38,238 (54%) 70,567
Race/ethnicity
  White, n (%) 13,159 (70%) 18,725
  Black, n (%) 3755 (20%) 18,725
  Hispanic, n (%) 105 (1%) 18,725
  Other, n (%) 1560 (8%) 18,725
clinical history
  Current smoker, n (%) 14,793 (27%) 55,002
  Diabetes mellitus, n (%) 22,895 (35%) 65,391
  Premature CHD in family, n (%) 9920 (40%) 25,070
  Left ventricular hypertrophy, n (%) 6284 (12%) 52,334
clinical and laboratory valuesb
  systolic blood pressure, mmHg 129 ± 17 70,036
  Diastolic blood pressure, mmHg 77 ± 11 70,032
  Total cholesterol, mmol/Lc 4.8 ± 1.1 69,949
  HDL-c, mmol/Lc 1.2 ± 0.3 69,363
  LDL-c, mmol/Lc 2.8 ± 0.9 69,474
  Triglycerides, mmol/Ld 1.7 ± 1.0 70,384
Notes: Age and clinical and laboratory values are presented as mean ± standard 
deviation.  aThe total number of patients available for each variable is ,70,567, 
reflecting missing data for the various elements. The exception is age and sex, which 
were required for all patients; bAll values are from the last recorded assessment. if 
the last assessment occurred .12 months before the last visit, the results were not 
used; cTo convert total, HDL-c and LDL-c levels from mmol/L to mg/dL, multiply 
by 38.61; dTo convert triglycerides from mmol/L to mg/dL, multiply by 88.50. 
Abbreviations:  cHD,  coronary  heart  disease;  cOseHc,  consortium  of 
southeastern  Hypertension  control;  HDL-c,  high-density  lipoprotein  cholesterol; 
LDL-c, low-density lipoprotein cholesterol.Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1140
Ferrario et al
0
0
10
20
30
40
50
60
70
80
10 20 30 40 50 60
C
O
S
E
H
C
-
1
7
 
v
a
r
i
a
b
l
e
 
r
i
s
k
 
s
c
o
r
e
COSEHC-11 variable risk score
Figure 1 COSEHC-17 versus COSEHC-11 risk score scatter plot with regression line and 95% confidence limits. The solid blue line shows the ordinary least-squares 
regression line (intercept = 3.19; slope = 1.05; R2 = 0.93; P , 0.0001). The thin green lines represent the 95% confidence bounds. The outliers above the 95% confidence limits 
included primarily patients with a history of stroke or myocardial infarction. These two variables, while heavily weighted in the cOseHc-17 score, were typically unreported 
in the electronic medical record system and were relatively uncommon even in the complete dataset.
Abbreviation: cOseHc, consortium for southeastern Hypertension control.
Table 3 Average cOseHc-11 score by site calculated with and without imputation
Site 1 Site 2 Site 3 Site 4 Site 5 Site 6 Site 7 Site 8 Total
Total populationa 2822 62,222 31,946 1319 4865 34,867 4930 34,433 177,404
No imputation
    Total available  
for analysis
1420 11,420 20,239 737 939 6047 13 2861 43,676
  cOseHc score 31.94 
(9.08)
31.95  
(10.76)
30.93  
(12.65)
31.07  
(9.53)
35.90  
(9.97)
31.18  
(11.08)
36.85  
(11.13)
36.60  
(9.46)
31.75  
(11.66)
Unlimited carry-forwardb
    Total available  
for analysis
1420 11,420 20,239 737 1124 6047 13 2861 43,861
  cOseHc score 31.94  
(9.08)
31.95  
(10.76)
30.93  
(12.65)
31.07  
(9.53)
36.13  
(9.70)
31.18  
(11.08)
36.85 
(11.13)
36.60  
(9.46)
31.77  
(11.65)
Pharmacy imputationc
    Total available  
for analysis
1420 11,420 20,239 737 1124 6047 13 2861 43,861
  cOseHc score 31.94  
(9.08)
31.95  
(10.76)
30.93  
(12.65)
31.07  
(9.53)
36.13  
(9.70)
31.18  
(11.08)
36.85  
(11.13)
36.60  
(9.46)
31.77  
(11.65)
Multiple imputationd
    Total available  
for analysis
1425 20,733 28,293 1127 2677 11,312 1963 3037 70,567
  cOseHc score 31.94  
(9.08)
31.72  
(10.85)
29.95  
(11.57)
30.65  
(9.47)
34.01  
(11.01)
31.26 
(11.42)
32.12  
(10.94)
36.75  
(9.45)
31.24  
(11.24)
Notes: All scores are presented as mean (standard deviation). aFor each site, total population includes all patients with $one visit in the eMR; bAccounts for laboratory and 
blood pressure values collected outside the original cutoff time of 12 months prior to inclusion; cAccounts for a missing history of diabetes from the eMR but the presence of 
diabetes-specific medications (insulin detemir, insulin glargine, human recombinant insulin, insulin lispro, metformin, pioglitazone, and rosiglitazone) in the pharmacy record; 
dAccounts for missing laboratory data from random visits using the Markov chain Monte carlo method. 
Abbreviations: cOseHc, consortium for southeastern Hypertension control; eMR, electronic medical record.Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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Translation of cOseHc scores  
into probability of cardiovascular death
The distribution of the COSEHC-11 score by decile for the 
43,676-member cohort is shown in Table 4. The median 
(ie, 50th percentile) score is 34, with a range of 0 to 62. The 
distribution of the estimated COSEHC-17 scores, calculated 
using the regression coefficients found in the Figure, are also 
presented, as is the corresponding probability of cardiovas-
cular death. Thus, for the median COSEHC-11 score of 34, 
which equates to an estimated COSEHC-17 score of 38.92, 
the cardiovascular death probability is 1.4%. A method 
for converting both the COSEHC-11 and COSEHC-17 
risk scores to cardiovascular death probability is shown in 
Table 5. Because the data are presented in a tabular form 
rather than as a continuous function, several closely spaced 
COSEHC scores may be inferred to yield the same event 
probability.
comparison of cOseHc, Framingham, 
PROCAM, and SCORE (Weibull)  
risk scores
Table 6 shows a comparison of the COSEHC, Framingham, 
PROCAM, and high- and low-risk SCORE (Weibull) risk 
scores calculated for men and women using both the complete 
and imputed GVRM data cohorts. Because the other three 
risk indices have different data requirements, the nonimputed 
sample sizes were smaller for Framingham (n = 23,683), 
PROCAM (n = 23,840), and SCORE (n = 23,787). For the 
imputed data cohort, the sample sizes also varied slightly 
across the Framingham, PROCAM, and COSEHC indices 
(Table 6). For all five risk scores, except PROCAM, the 
average man in the cohort had a higher risk than the average 
woman. The average Framingham scores reported for the full 
cohort correspond to a 10-year risk of fatal or nonfatal CHD 
events of 12.55% for men and 5.90% for women; in the 
imputed cohort, the risks are 11.93% and 5.47%, respec-
tively. Using the PROCAM score, the probability of fatal or 
nonfatal CHD events in men was nearly two-fold higher than 
the probability calculated using the Framingham score, while 
the predicted risk in women was almost four-fold higher. The 
SCORE (Weibull) risk score has both a high- and low-risk 
algorithm, and both scores were calculated for all patients 
because the exponential functions used in this calculation 
imply that small changes in certain combinations of variables 
could create disproportionate changes in the final score. 
Upon multiple imputation and for both men and women, 
the 10-year risk of fatal CHD calculated using the SCORE 
low-risk algorithm is similar to the COSEHC-11 score, which 
predicts the five-year risk of fatal CHD. When the SCORE 
high-risk algorithm is used, the risk in men and women is 
roughly twice that calculated using the COSEHC-11 score 
(1.9-fold and 1.7-fold, respectively).
Table 7 shows the correlations between each of the 
five risk scores. The strongest correlations were between 
the COSEHC-11 and COSEHC-17 scores (R2 = 0.93) 
and between the SCORE low- and high-risk algorithms 
(R2 = 0.99). This is as expected because COSEHC-11 and 
COSEHC-17 and the SCORE algorithms assess the risk 
of the same endpoints (five-year fatal cardiac events for 
COSEHC and 10-year fatal cardiac events for SCORE). The 
correlation between scores that predict the risk of different 
endpoints was not as high. For example, the correlation 
between the COSEHC-11 risk score and the Framingham risk 
score, which assesses the 10-year risk of fatal and nonfatal 
cardiac events, was only 0.36. Although the Framingham 
and PROCAM scores both predict the 10-year risk of fatal 
and nonfatal cardiac events, their correlation was only 0.36. 
This poor correlation may be due to the fact that the variables 
included in the risk algorithms are different.
Discussion
In this analysis of 177,404 patients enrolled in the COSEHC 
GVRM study, 43,676 patients had complete data for all 
11 risk factors that comprise the COSEHC-11 cardiovascular 
risk score, and an additional 26,891 had at least eight of the 
11 required variables. The mean COSEHC-11 risk score for 
the 43,676 patients who had available data for all 11 vari-
ables was 31.75. The inclusion of multiple imputations to 
Table 4 Translation of cOseHc-11 score to cOseHc-17 score
Percentile  COSEHC-11 
scorea
COSEHC-17 
scoreb
Event 
probabilityc
0 0 3.19 0.04%
10 14 17.91 0.19%
20 21 25.26 0.51%
30 27 31.57 0.84%
40 31 35.77 1.40%
50 34 38.92 1.40%
60 36 41.03 2.30%
70 40 45.23 3.70%
80 42 47.33 3.70%
90 44 49.43 3.70%
100 62 68.35 24.50%
Notes: given there are 43,676 patients with all data necessary to calculate the 
COSEHC-11 risk score, there are approximately 4367 patients per decile (eg, 4367 
patients between percentiles 0 and 10).  acalculated for the 43,676 patients with 
complete cOseHc-11 data; bcalculated using the results of the logistic regression 
model (COSEHC-17 = 3.19480 + 1.05084 * COSEHC-11); cFive-year risk of fatal 
coronary heart disease events. 
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Table 6 Cardiovascular event probability calculated using the COSEHC-11, Framingham, PROCAM, and SCORE (Weibull) risk scores
Framinghama  PROCAMa SCOREb low-risk  SCOREb high-risk  COSEHC-11c 
No imputation
Men, n 11,006 11,163 11,136 11,136 16,951
  Probability 12.55 (7.74) 20.07 (20.68) 2.48 (2.62) 4.96 (4.96) 3.15 (2.05)
Women, n 12,677 12,677 12,651 12,651 26,725
  Probability 5.90 (5.84) 20.19 (22.22) 1.63 (2.31) 2.76 (3.76) 1.62 (1.81)
Multiple imputationd
Men, n 31,825 32,329 32,082 32,082 32,329
  Probability 11.93 (7.79) 19.75 (21.52) 2.54 (2.86) 5.07 (5.38) 2.68 (2.06)
Women, n 38,238 38,238 38,013 38,013 38,238
  Probability 5.47 (5.69) 19.68 (22.64) 1.62 (2.42) 2.75 (3.93) 1.65 (1.81)
Notes: All scores are presented as mean (standard deviation). aPredicts 10-year risk of fatal or nonfatal cHD events; bPredicts 10-year risk of fatal cHD events; cPredicts 
five-year risk of fatal CHD events; dAccounts for missing laboratory data from random visits using the Markov chain Monte carlo method. 
Abbreviations:  cHD,  coronary  heart  disease;  cOseHc,  consortium  for  southeastern  Hypertension  control;  PROcAM,  Prospective  cardiovascular  Münster; 
scORe, systemic coronary Risk evaluation.
Table 5 event probabilities associated with ranges of cOseHc-11 and cOseHc-17 scores
COSEHC-17 
lower  bound
COSEHC-17 
upper bound
Event  
probabilitya
Range COSEHC-11  
lower bound
COSEHC-11 
upper bound
Event  
probabilitya
Range
0.00 to 4.99 0.04% 4.99 –3.04 to 1.71 0.04% 4.75
5.00 to 9.99 0.07% 4.99 1.72 to 6.47 0.07% 4.75
10.00 to 14.99 0.11% 4.99 6.48 to 11.22 0.11% 4.75
15.00 to 19.99 0.19% 4.99 11.23 to 15.98 0.19% 4.75
20.00 to 24.99 0.31% 4.99 15.99 to 20.74 0.31% 4.75
25.00 to 29.99 0.51% 4.99 20.75 to 25.50 0.51% 4.75
30.00 to 34.99 0.84% 4.99 25.51 to 30.26 0.84% 4.75
35.00 to 39.99 1.40% 4.99 30.27 to 35.01 1.40% 4.75
40.00 to 44.99 2.30% 4.99 35.02 to 39.77 2.30% 4.75
45.00 to 49.99 3.70% 4.99 39.78 to 44.53 3.70% 4.75
50.00 to 54.99 6.10% 4.99 44.54 to 49.29 6.10% 4.75
55.00 to 59.99 9.80% 4.99 49.30 to 54.05 9.80% 4.75
60.00 to 64.99 15.60% 4.99 54.06 to 58.81 15.60% 4.75
65.00 to 69.99 24.50% 4.99 58.82 to 63.56 24.50% 4.75
70.00 and up 37.90% 63.57 and up 37.90%
Note: aProbability of fatal cardiovascular event over five years.
Abbreviation: cOseHc, consortium for southeastern Hypertension control.
account for missing data points had a minimal impact on 
the mean COSEHC-11 risk score for the 70,567 patients 
who had at least eight of the 11 variables. In addition, linear 
regression analysis showed that the COSEHC-11 score was 
a significant predictor of the original, more comprehensive 
COSEHC-17 score. The high degree of correlation between 
the COSEHC-11 and 17 scores suggests that the simpler 
COSEHC-11 score is just as effective at predicting cardio-
vascular risk as the COSEHC-17 score, and can therefore 
be used to predict cardiovascular morbidity and mortality 
in patients whose electronic medical record may be lacking 
data for all 17 variables. Calculation of the Framingham, 
PROCAM, and high- and low-risk SCORE (Weibull) risk 
scores revealed that, for all but the PROCAM score, men 
have a higher predicted risk than women.
Aside from assessing achievement of COSEHC-
recommended treatment goals and providing participating 
centers with benchmarking reports, one of the objectives 
of the GVRM study is to analyze the correlation between 
the COSEHC, Framingham,12 PROCAM,20 and SCORE 
(Weibull)21 coronary risk scores and the time to the first fatal 
(COSEHC, Framingham, PROCAM, and SCORE) or non-
fatal (Framingham and PROCAM) coronary event over the 
five-year study duration to determine which score is most pre-
dictive for patients in the southeastern US. Although no single 
risk score is likely to be perfectly correlated with outcomes 
in all populations due to inherent variability, it is desirable 
to determine which score is most predictive for the majority 
of situations in a given population. Data suggest that the 
Framingham coronary risk score tends to overestimate risk, Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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particularly in nonwhite populations due to the   derivation of 
the score from a primarily white cohort.12,13,16–19,29–31 Although 
the PROCAM and SCORE (Weibull) coronary risk scores 
were partly developed to address the limitations of the 
Framingham cardiovascular risk score, external validation 
data suggest that the PROCAM and SCORE (Weibull) risk 
scores also tend to overestimate coronary risk.18,19,31–33
In the current era of rising health care costs and the 
increased pressure to provide adequate health care coverage 
for all persons, it is important to identify a patient’s true risk 
of coronary events correctly. For example, if a risk score 
systematically overestimates cardiovascular risk, then health 
care resources will be unnecessarily used and patients may be 
exposed to potentially unnecessary treatments.29 Conversely, 
if a risk score systematically underestimates cardiovascu-
lar risk, patients will be less likely to receive appropriate 
treatment, and resource utilization may increase due to the 
occurrence of more acute events. Thus, identification of a 
region-specific, accurate coronary risk score is desirable.
A unique aspect of the COSEHC GVRM study is the use 
of electronic medical records and the ease of data collection 
and validation. Using data from the patient’s actual medical 
record and not that recorded on a study-specific report form 
is more representative of the care patients receive in the “real 
world.” Another strength of the COSEHC GVRM study is 
that it includes only patients enrolled at COSEHC Centers 
of Excellence. Thus, it provides a unique tool for directly 
assessing the population living in the southeastern US, which 
has a different racial and ethnic composition compared with 
other areas of the US.
The COSEHC GVRM study does have several limita-
tions. Although not proven, physicians at COSEHC Centers 
of Excellence may provide better care for their patients, 
and thus, the risk observed in the GVRM study cohort may 
underestimate the risk observed in the general population. 
This possibility is reflected in the high frequency of patients 
with controlled blood pressure (mean systolic blood pressure 
of 129 ± 17 mmHg) and lipid levels (mean plasma total 
cholesterol 4.8 ± 1.1 mmol/L [184 ± 42 mg/dL], HDL-C 
1.2 ± 0.3 mmol/L [47 ± 13 mg/dL], and triglyceride levels 
1.7 ± 1.0 mmol/L [151 ± 87 mg/dL]) at study baseline. The 
ability to obtain certain patient demographics and clinical 
history variables from electronic medical records, including 
ethnicity, premature family CHD, history of LVH, smoking, 
and diabetes, can be difficult and is dependent on the elec-
tronic medical record system design, the effort of clinicians 
to report patient history, and, in some cases, the ability and 
willingness of patients to self-report history and demographic 
data. For example, family CHD history and LVH history 
are difficult to observe because they are not represented by 
an ICD-9 code and may only appear in a free-text comment 
area. Furthermore, the lack of a standardized definition of 
history of premature family CHD among providers, and it 
not being considered clinically important for older patients, 
suggests it may go unreported. In addition, while performance 
of echocardiography is typically reported in an electronic 
medical record, the objective test results defining LVH are 
not always included. Finally, as is true for any nonrandom-
ized registry study, the influence of recruitment bias cannot 
be known.
In conclusion, these baseline data from the COSEHC 
GVRM study show there is excellent correlation between 
the original COSEHC-17 and the modified COSEHC-11 
cardiovascular risk scores (P , 0.0001; R2 = 0.93). Follow-up 
data collected over the next five years will demonstrate the 
predictive ability of the COSEHC cardiovascular risk score 
Table 7 Correlation between the COSEHC-11, COSEHC-17, Framingham, PROCAM, and SCORE (low- and high-risk algorithms) 
risk scores
COSEHC-11a COSEHC-17a Framinghamb PROCAMb SCORE (Weibull)c 
low-risk
SCORE (Weibull)c 
high-risk
cOseHc-11a 1.00
cOseHc-17a 0.93 1.00
Framinghamb 0.36 0.35 1.00
PROcAMb 0.37 0.39 0.36 1.00
SCORE (Weibull)c 
low-risk
0.52 0.49 0.15 0.27 1.00
SCORE (Weibull)c 
high-risk
0.52 0.48 0.11 0.24 0.99 1.00
Notes: correlation was calculated using multiple regression analysis. aPredicts the five-year risk of fatal CHD events; bPredicts the 10-year risk of fatal and nonfatal cHD 
events; cPredicts the 10-year risk of fatal cHD events. 
Abbreviations:  cHD,  coronary  heart  disease;  cOseHc,  consortium  for  southeastern  Hypertension  control;  PROcAM,  Prospective  cardiovascular  Münster; 
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relative to the more widely used Framingham, PROCAM, 
and SCORE (Weibull) risk scores among patients in the 
southeastern US.
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